First, mogamulizumab has been approved in Japan for relapsed or refractory CCR4+ adult T-cell leukemia-lymphoma (2012), PTCL (2014), and CTCL (2014) (35). This evidence concerns the gene CCR4 and adult T-cell leukemia/lymphoma.